·
· METHODS:Totally60patients(60eyes)withahistory ofacuteCSCRwererandomedintotwogroups:groupA with combination of fenofibrate (200 mg) and spironolactone (100 mg), and group B with only fenofibrate(200mg).Theyweretakenhalfanhourbefore mealsandonceperdayfor8wk.Thechangesofthe visualacuity,subjectivesymptom,ocularsurfacedisease index (OSDI),thetear filmand opticalcoherence tomographywereobservedat2,4,6,and8wkbeforeand aftertreatment.
· RESULTS:Thebestcorrectedvisualacuity(BCVA, logMAR)wasimprovedto0.22and0.27aftertreatment frombaselineof0.35and0.36ingroupsAandB ( < 0.05), respectively. After 8wk treatment, the central subfieldthickness (CST),andsubretinalfluidvolumn (SFV)decreasedsignificantlyto49.5%and78.8%in groupA,37.0%and57.2% ingroupB.Therewere significantdifferencesofCSTandSFVinbothgroups (all <0.05).
· CONCLUSION:Fenofibratecombinedwithspironolactone mayhavemoreclinicalefficacyinthetreatmentofCSCR thanfenofibrateonly.
INTRODUCTION
C entralserouschorioretinopathy(CSCR)isavisionthreateningdiseasecharacterizedbyseroussubretinal fluid(SRF)accumulationcausingalocalizedareaofretinal detachment [1] .VonGr覿fe(1866)firstreportedthispathology withcommonclinicalsymptoms,suchasvisualdistortion, narrowing,floatingshadows,andvisionloss.Theincidence ofthisdisordercontinuestoincrease.CSCRaffectsabout1 in10000people,withmenaffectedmorecommonlythan women [2] [3] .Itpossessesalongcourse,aseveresymptomand hasbeenakeyissueinrecentresearch.Thehighspontaneous remissionratefavorsconservativemanagement,lifestyle counseling,anddiscontinuationofglucocorticoidmedication asfirst-linetherapeuticoptions.Unfortunately,manycasesof acuteCSCRarenoteligibleordonotrespondtotreatment withthermallaserorphotodynamictherapy [4] . Fenofibratecouldinterferewiththemultiplemechanismsof CSCR,suchasreducingplasmalipids [5] ,improving endothelialfunction,inhibitingexcessiveexpressionof inflammatoryfactors [6] ,reducingapoptosisintheretina [7] , andinhibitingtheformationofvascularendothelialgrowth factor(VEGF) [8] .Spironolactoneisasynthesisofaldosterone receptorantagonist,whichwaseffectiveininhibitingplatelet aggregationandtheformationofnewvessels [9] . [14] .Withoutearlytreatment, long-termmacularedemawoulddamagevisualfunctionin somepatients,whichultimatelyleadstodegenerationof visualcells.Thathasnotyetfullyunderstood,butvarious studieshaveshownthatitmightbeassociatedwith corticosteroids,drinking,ordecreased functionofthe immunesystem.WhileitistruethatexactcauseofCSCRthe durationofdetachment,themechanismbywhichthisis achievedremainscontroversial.Spitznas [15] hasreviewedthe experimentalevidenceonthenatureoftheRPEabnormality, whichpostulatedareversalinthedirectionofwatertransport acrosstheabnormalRPE-suchthatthisoccursfromthe choroidtowardstheneuroretina.Inaddition,elevatedserum cholesterolleadstomacularedemaandhardexudation, whichisassociatedwiththedevelopmentandseverityof CSCR.Morespecifically,anelevationintriglyceridesis associatedwithmacularedemaandhardexudation.Blood circulationdrugsandglucocorticoidantagonisthavebeenthe traditionaltreatmentforthisdisease.However,thistypeof drugshasthepotentialtoworsensymptoms,causeinterlayer effusion,recurrence,and/orvisualdistortionforpatientswith retinalmacularedema.Thisposesaseriousthreattovisual acuity.LaserphotocoagulationtreatmentonlyclosestheRPE leakagebylaserthermaleffects,butdoesnotreducethe abnormalchoroidalbloodflow,however,PDTtreatment coulddecreasechoroidalthicknessbyreducingtheabnormal choroidalbloodflow [16] .Theyalsohavethepotentialtoelicit non-selectivecoagulationnecrosisontheadjacenttissueof lesionarea,whichwouldresultinseveraladverseeffects, suchastheformationofcentralscotoma,thereduction of contrastsensitivity,andsecondarychoroidal neovascularization.Intravitrealanti-VEGFtherapyhasbeen demonstratedwithprofitableresultsinseveralchronic CSCR [17] [18] [19] [20] .Nevertheless,large-scalemulticenterclinical controlledtrialsarenecessarytoevaluatetheefficacyand safetyof anti-VEGF therapyforCSCR.Inaddition, virectomyisineffectiveforCSCR.Thus,furtheringthe understandingofthemechanismofangiogenesis,making [21] [22] .Taking200mgoffenofibratedaily failedtoaffectvisualacuitymeasures,butcouldsignificantly decreasetheneedforusinglasertreatmentinpatientswith diabeticmacularedemaandproliferativeretinopathy,andit promotes30%oftheabsorptionofmacularedema [23] .These findingshaveresultedinrecommendationsthatfenofibratebe usedasanadjuncttreatmentfortype2diabeticpatientswith nonproliferativediabeticretinopathy [24] [25] . Asweknow,glucocorticoidsisassociatedwithCSCRand glucocorticoidsshowstosomeextentanaffinityforthe mineralocorticoidreceptor(MR).Ithasbeenproposedthat excessiveglucocorticoid-dependentchoroidalMRactivation inchoroidvesselsmaybeinvolvedinthepathogenesisof CSCR [26] .Zhao [27] haveobservedinratstudiesthat intravitreousinjectionofaspecificMRactivatoraldosterone, induceddilationofchoroidalvesselsandleakage.Similar observationshavebeenconfirmedonhumanM俟llerglialcell lines [28] .MRisexpressedinneuroretinaandchoroid; excessiveMRactivationmaypromotevascularoxidative stressandinhibitvascularrelaxation.Subsequently,itmay contributetovesselinflammation,fibrosisandremodeling, andleadtochoroidalandretinalneovascularization. SpironolactoneasastrongMRantagonists,caninhibitthe formationofnewbloodvessels [29] [30] ,inhibitionofplatelet aggregation,vascularendothelialfunctiontorecoverleakage ofthechoroidalvasculatureanddecreasechoroidalthickness. 
